Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath
Lisa G
LG
Sydney Cancer Centre, Camperdown, New South Wales, Australia.
Henshall
Susan M
SM
Lee
C-Soon
CS
Kench
James G
JG
Golovsky
David
D
Brenner
Phillip C
PC
O'Neill
Gordon F
GF
Kooner
Raji
R
Stricker
Phillip D
PD
Grygiel
John J
JJ
Sutherland
Robert L
RL
D000293:Adolescent; D000328:Adult; D000368:Aged; D015820:Cadherins / Q000378:metabolism; D016022:Case-Control Studies; D002467:Cell Nucleus / Q000378:metabolism*; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011237:Predictive Value of Tests; D011379:Prognosis; D011467:Prostate / Q000378:metabolism / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D012307:Risk Factors; D015996:Survival Rate; D015534:Trans-Activators / Q000378:metabolism*; D051176:beta Catenin
C495270:CTNNB1 protein, human; D015820:Cadherins; D003598:Cytoskeletal Proteins; D015534:Trans-Activators; D051176:beta Catenin; D017430:Prostate-Specific Antigen